{"id":"W4324136398","doi":"10.1200/jco.2023.41.6_suppl.22","title":"Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Ipilimumab; Cabazitaxel; Nivolumab; Docetaxel; Abiraterone acetate; Prostate cancer; Cohort; Prednisone; Randomized controlled trial; Oncology; Taxane; Chemotherapy; Clinical trial; Cancer; Androgen deprivation therapy; Breast cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001399804,0.0008835437,0.001074364,0.0002912823,0.0002223748,0.000758965,0.0005524942,0.000788359,0.006538438],"category_scores_gemma":[0.0009862055,0.0003261372,0.001163185,0.000303851,0.0004427428,0.0005001308,0.000303407,0.001528878,0.0005820462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007271275,"about_ca_system_score_gemma":0.0007807632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00124869,"about_ca_topic_score_gemma":0.003299258,"domain_scores_codex":[0.999693,0.0001709726,0.00001391347,0.00004345929,0.00002344587,0.00005516981],"domain_scores_gemma":[0.9994426,0.0001426153,0.0001372501,0.00005000948,0.00002479746,0.000202679],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9391237,0.01173675,0.002733308,0.0006350178,0.001061577,0.00007310763,0.00007781807,0.0008652147,0.005924441,0.0001612288,0.00221483,0.03539305],"study_design_scores_gemma":[0.8855893,0.1020457,0.008126971,0.00004071995,0.0008172104,0.0001069632,0.00002521576,0.0005427794,0.0008762201,0.0001396179,0.001673473,0.00001584307],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925786,0.00223077,0.0002643977,0.0002563111,0.000119616,0.001442501,0.001257239,0.00006971909,0.001780875],"genre_scores_gemma":[0.9926251,0.001236677,0.0006958797,0.0005177895,0.0001379817,0.00109873,0.001888323,0.00001738563,0.00178219],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006538438,"threshold_uncertainty_score":0.0218733,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2058361179828932,"score_gpt":0.5215913805671609,"score_spread":0.3157552625842677,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}